
|Articles|October 25, 2013
- Genitourinary Cancers
- Volume 1
- Issue 1
Sequencing Agents to Treat Castration-Resistant Prostate Cancer
Leonard G. Gomella, MD, FACS, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer.
Advertisement
Leonard G. Gomella, MD, FACS, Chair and Professor, Department of Urology, Thomas Jefferson University, Associate Director, Clinical Affairs, Kimmel Cancer Center, comments on sequencing agents to treat castration-resistant prostate cancer (CRPC).
Read more about immunotherapy for the treatment of CRPC > >
Articles in this issue
about 12 years ago
Patient-Centered Management of Metastatic Renal Cell Carcinomaabout 12 years ago
Expert Perspectives: Androgen-Deprivation Therapy in Prostate Cancerabout 12 years ago
Treatment of Advanced Renal Cell Carcinomaabout 12 years ago
Treatment Pathways and Sequencing Strategies in CRPCabout 12 years ago
Therapeutic Strategies for Managing Bone Health in Prostate Cancerabout 12 years ago
Immunotherapy in CRPCabout 12 years ago
Factors in Choosing First-Line Targeted Therapy in RCCabout 12 years ago
Immune Response in Patients with RCCabout 12 years ago
Frontline Treatment of Kidney Cancer With Pazopanib and SunitinibAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5






































